Plain-English translation of NCT07239245 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a three-part treatment approach given before surgery for people with liver cancer that has a high chance of coming back. You would receive plus — two medications that work with your immune system to fight cancer — combined with a procedure called transarterial chemoembolization, which delivers cancer-fighting drugs directly to the tumor through a thin tube in your blood vessels. The goal is to shrink the cancer before surgery and reduce the risk that it will return.
Even after surgery, liver cancer often comes back, especially in patients whose tumors are large, numerous, or have other high-risk features. This trial is testing whether giving this medication and procedure before surgery can improve the chances of keeping the cancer from returning and help patients live longer.
You likely qualify if…
You likely don't qualify if…
You would receive five cycles of the medication combination over about 3.5 months, with each cycle lasting 21 days. During this time, you would also undergo two to three procedures where doctors use a thin catheter to deliver chemotherapy drugs directly to your tumors. After completing the medication cycles and procedures, you would proceed to surgery to remove the cancer. You'll have regular doctor visits, blood tests, and imaging scans to monitor how the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China